



Andrés Suárez and Antonio Pizzano*

Tetrahedron: Asymmetry 12 (2001) 25012-(Diphenylphosphino)phenyl-(S)-3,3'-di-*tert*-butyl-5,5',6,6'-tetramethyl-1,1'-biphen-2,2'-diyl-phosphite

Ee = 100%

 $[\alpha]_D^{20} = 406$ (*c* 1.0, THF)Source of chirality: (S)-3,3'-di-*tert*-butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diol


Andrés Suárez and Antonio Pizzano*

Tetrahedron: Asymmetry 12 (2001) 25012-(Dimethylphosphino)phenyl-(S)-3,3'-di-*tert*-butyl-5,5',6,6'-tetramethyl-1,1'-biphen-2,2'-diyl-phosphite

Ee = 100%

 $[\alpha]_D^{20} = 347$ (*c* 1.0, THF)Source of chirality: (S)-3,3'-di-*tert*-butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diol


Andrés Suárez and Antonio Pizzano*

Tetrahedron: Asymmetry 12 (2001) 25012-(Diisopropylphosphino)phenyl-(S)-3,3'-di-*tert*-butyl-5,5',6,6'-tetramethyl-1,1'-biphen-2,2'-diyl-phosphite

Ee = 100%


 $[\alpha]_D^{20} = 336$ (*c* 1.0, THF)Source of chirality: (S)-3,3'-di-*tert*-butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diol

Andrés Suárez and Antonio Pizzano*

Tetrahedron: Asymmetry 12 (2001) 2501(S)-2-(Methylphenylphosphino)phenyl-3,3',5,5'-tetra-*tert*-butyl-1,1'-biphen-2,2'-diyl-phosphite

Ee = 100%

 $[\alpha]_D^{20} = 1.6$ (*c* 1.0, THF)Source of chirality: (S)-*o*-anisylmethylphenylphosphine

 $C_{10}H_{10}O_5$


6-Formyl-1-methoxycarbonylbicyclo[3.1.0]hex-2-ene-2-carboxylic acid

E.e. = 100%

 $[\alpha]_D = -152.7$ ($c = 0.74$, MeOH)

Source of chirality: asymmetric synthesis from mannitol

Absolute configuration: 1S,5R,6S

 $C_{11}H_{12}O_5$


6-Formyl-1-ethoxycarbonylbicyclo[3.1.0]hex-2-ene-2-carboxylic acid

E.e. = 100%

 $[\alpha]_D = -127.0$ ($c = 3.1$, MeOH)

Source of chirality: asymmetric synthesis from mannitol

Absolute configuration: 1S,5R,6S

 $C_{12}H_{14}O_5$


6-Formyl-1-propoxycarbonylbicyclo[3.1.0]hex-2-ene-2-carboxylic acid

E.e. = 100%

 $[\alpha]_D = -217.0$ ($c = 0.35$, MeOH)

Source of chirality: asymmetric synthesis from mannitol

Absolute configuration: 1S,5R,6S

 $C_{10}H_{10}O_4$


3-Methoxycarbonylbicyclo[2.2.1]hept-2,5-diene-2-carboxylic acid

E.e. = 100%

 $[\alpha]_D = -25.7$ ($c = 1.9$, CHCl₃)

Source of chirality: asymmetric synthesis from mannitol

Absolute configuration: 2S,3R


 $C_{11}H_{12}O_4$

3-Ethoxycarbonylbicyclo[2.2.1]hept-2,5-diene-2-carboxylic acid

E.e.=100%

 $[\alpha]_D = -15.4$ ($c = 2.7$, $CHCl_3$)

Source of chirality: asymmetric synthesis from mannitol


Absolute configuration: 2*S*,3*R* $C_{12}H_{14}O_4$

3-Propoxycarbonylbicyclo[2.2.1]hept-2,5-diene-2-carboxylic acid

E.e.=100%

 $[\alpha]_D = -10.2$ ($c = 1.9$, $CHCl_3$)

Source of chirality: asymmetric synthesis from mannitol


Absolute configuration: 2*S*,3*R* $C_8H_{10}O_2$

(S)-1-Phenylethane-1,2-diol

E.e.=100%

 $[\alpha]_D^{18} = +71.9$ (c 1.0, $CHCl_3$)

Source of chirality: microbial reduction


Absolute configuration: *S* $C_9H_{12}O_3$ (S)-1-*p*-Methoxyphenylethane-1,2-diol

E.e.=100%

 $[\alpha]_D^{23} = +64.5$ (c 1.0, $CHCl_3$)

Source of chirality: microbial reduction

Absolute configuration: *S*




$C_{10}H_{12}O_4$
(*S*)-1-Benzoyloxy-2,3-propanediol

E.e.=80%

 $[\alpha]_D^{23}=+4.1$ (*c* 0.94, CH_3CH_2OH)

Source of chirality: microbial reduction


Absolute configuration: *S*

$C_{10}H_{14}O_2$
(*S*)-4-Phenyl-1,2-butanediol

E.e.=94%

 $[\alpha]_D^{20}=-32.3$ (*c* 1.0, CH_3CH_2OH)

Source of chirality: microbial reduction


Absolute configuration: *S*

$C_8H_9ClO_2$
(*S*)-1-*p*-Chlorophenylethane-1,2-diol

E.e.=100%

 $[\alpha]_D^{18}=+59.5$ (*c* 1.1, $CHCl_3$)

Source of chirality: microbial reduction

Absolute configuration: *S*


$C_{10}H_{14}O_3$
(*R*)-1-Benzylxy-2,3-propanediol

E.e.=73%

 $[\alpha]_D^{20}=-0.98$ (*c* 1.0, $CHCl_3$)

Source of chirality: microbial reduction

Absolute configuration: *R*




$C_9H_{12}O_3$
(*R*)-1-Phenoxy-2,3-propanediol

E.e.=88%

 $[\alpha]_D^{20} = -1.6$ (*c* 1.0, CHCl₃)

Source of chirality: microbial reduction


Absolute configuration: *R*

$C_{12}H_{17}NO_4$
Methyl 4-(2'*R*-carboxypropyl)-3,5-dimethyl-1*H*-pyrrole-2-carboxylate

E.e.=100%

 $[\alpha]_D^{20} = -51.2$ (*c* 1.2, CHCl₃)

Source of chirality: resolution


Absolute configuration: (*αR*) (assigned by X-ray of amide with camphor sultam)

$C_{22}H_{32}N_2O_5S$
N-[3-(2,4-Dimethyl-5-methoxycarbonyl-1*H*-pyrrol-3-yl)-(2*R*)-methylpropanoyl]-camphor-2',10'-sultam

E.e.=100%

 $[\alpha]_D^{20} = -92.2$ (*c* 1.2, CHCl₃)

Source of chirality: resolution by crystallization

Absolute configuration: (1*S*,2*R*,4*R*,*αR*) (assigned by X-ray)


$C_{19}H_{26}N_2O_3$
Methyl (*αR*)-methylxanthobilirubinate

E.e.=100%

 $[\alpha]_D^{20} = -55.8$ (*c* 0.3, CHCl₃)

Source of chirality: synthesis and resolution

Absolute configuration: (*αR*) (assigned by X-ray of monopyrrole precursor)


 $C_{37}H_{46}N_4O_6$

(αR,α'R)-Dimethylmesobiliverdin-XIIIα dimethyl ester

E.e. = 100%

 $[\alpha]_{D}^{20} = +2190$ (*c* 4.3 × 10⁻³, CHCl₃)

Source of chirality: synthesis and resolution


Absolute configuration: (α*R*,α'*R*) (assigned by X-ray of monopyrrole precursor) $C_{37}H_{48}N_4O_6$

(αR,α'R)-Dimethylmesobilirubin-XIIIα dimethyl ester

E.e. = 100%

 $[\alpha]_{D}^{20} = +240$ (*c* 5.0 × 10⁻³, CHCl₃)CD: $\Delta\epsilon_{413}^{\max} = +36$, $\Delta\epsilon_{375}^{\max} = -22$ (*c* 1.5 × 10⁻⁵ M, CHCl₃)

Source of chirality: synthesis and resolution


Absolute configuration: (α*R*,α'*R*) (assigned by X-ray of monopyrrole precursor) $C_{35}H_{44}N_4O_6$

(αR,α'R)-Dimethylmesobilirubin-XIIIα

E.e. = 100%

 $[\alpha]_{D}^{20} = +5530$ (*c* 5.0 × 10⁻³, CHCl₃)CD: $\Delta\epsilon_{435}^{\max} = +344$, $\Delta\epsilon_{391}^{\max} = -193$ (*c* 1.4 × 10⁻⁵ M, CHCl₃)

Source of chirality: synthesis and resolution

Absolute configuration: (α*R*,α'*R*) (assigned by X-ray of monopyrrole precursor) $C_{35}H_{44}N_4O_6$


(αR,β'S)-Dimethylmesobilirubin-XIIIα

E.e. = 100%

 $[\alpha]_{D}^{20} = +2720$ (*c* 4.9 × 10⁻³, CHCl₃)CD: $\Delta\epsilon_{430}^{\max} = +165$, $\Delta\epsilon_{386}^{\max} = -100$ (*c* 1.5 × 10⁻⁵ M, CHCl₃)

Source of chirality: synthesis and resolution

Absolute configuration: (α*R*,β'*S*) (assigned by X-ray of monopyrrole precursor)




$[\alpha]_{D}^{25} = -358$ (*c* 0.3; MeOH)

Absolute configuration aR (assigned by analogy)

C₂₇H₂₁NO₂

2',1':1,2;1'',2'':3,4-Dinaphthycyclohepta-1,3-diene-6-cyano-6-carboxylic acid ethyl ester




$[\alpha]_{D}^{25} = -297$ (*c* 0.2; MeOH)

Absolute configuration aR (assigned by analogy)

C₂₇H₂₅NO₂

2',1':1,2;1'',2'':3,4-Dinaphthycyclohepta-1,3-diene-6-aminomethyl-6-carboxylic acid ethyl ester (H-β^{2,2}-HBin-OEt)




$[\alpha]_{D}^{25} = +299$ (*c* 0.1; MeOH)

Absolute configuration aS (assigned by analogy)

C₂₆H₂₃NO₂

2',1':1,2;1'',2'':3,4-Dinaphthycyclohepta-1,3-diene-6-aminomethyl-6-carboxylic acid methyl ester (H-β^{2,2}-HBin-OMe)




$[\alpha]_{D}^{25} = -178$ (*c* 0.2; MeOH)

Absolute configuration aR (assigned by analogy)

C₃₂H₃₃NO₄

2',1':1,2;1'',2'':3,4-Dinaphthycyclohepta-1,3-diene-6-N-tert-butyloxycarbonylaminomethyl-6-carboxylic acid ethyl ester (Boc-β^{2,2}-HBin-OEt)




C₃₁H₃₁NO₄

2',1':1,2;1'',2'':3,4-Dinaphthycyclohepta-1,3-diene-6-N-tert-butyloxycarbonylaminomethyl-6-carboxylic acid methyl ester (Boc- $\beta^{2,2}$ -HBin-OMe)

[α]₅₄₆²⁵ = +179 (c 0.2; MeOH)

Absolute configuration aS (assigned by analogy)




C₃₀H₂₉NO₄

2',1':1,2;1'',2'':3,4-Dinaphthycyclohepta-1,3-diene-6-N-tert-butyloxycarbonylaminomethyl-6-carboxylic acid (Boc- $\beta^{2,2}$ -HBin-OH)

[α]₅₄₆²⁵ = +215 (c 0.2; MeOH)

Absolute configuration aS (assigned by analogy)




C₂₇H₂₂F₃NO₄

2',1':1,2;1'',2'':3,4-Dinaphthycyclohepta-1,3-diene-6-aminomethyl-6-carboxylic acid, trifluoroacetate (H- $\beta^{2,2}$ -HBin-OH, CF₃COOH)

[α]₅₄₆²⁵ = -255 (c 0.2; MeOH)

Absolute configuration aR (assigned by analogy)




C₄₇H₄₅N₃O₃


Bz-(R)- $\beta^{2,2}$ -HBin-(L)-Phe-NHC₆H₁₁

[α]₅₄₆²⁵ = -11 (c 0.1; MeOH)

Absolute configuration aR,S (assigned by analogy)




$[\alpha]_{D}^{25} = +141$ (*c* 0.15; MeOH)
Absolute configuration a,S,S (assigned by analogy)




$C_{24}H_{21}BrO_4$
6-Bromo-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene

$[\alpha]_D^{28} = +59.1$ (*c* = 0.45, CHCl₃)
Source of chirality: BINOL
Absolute configuration: *R*




$C_{25}H_{22}O_5$
6-Formyl-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene

$[\alpha]_D^{28} = +57.6$ (*c* = 0.45, CHCl₃)
Source of chirality: BINOL
Absolute configuration: *R*



$C_{25}H_{24}O_5$
6-Hydroxymethyl-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene

$[\alpha]_D^{29} = +57.0$ (*c* = 0.45, CHCl₃)
Source of chirality: BINOL
Absolute configuration: *R*




$C_{34}H_{32}O_5$
6-(4-Vinylbenzyloxy)methyl-2,2'-bismethoxymethoxy-1,1'-binaphthalene

$[\alpha]_D^{27} = +43.3$ ($c = 1$, CHCl₃)

Source of chirality: BINOL

Absolute configuration: *R*




$C_{30}H_{24}O_3$
6-(4-Vinylbenzyloxy)methyl-2,2'-dihydroxy-1,1'-binaphthalene

$[\alpha]_D^{28} = -46.9$ ($c = 0.48$, CHCl₃)

Source of chirality: BINOL

Absolute configuration: *R*




$C_{16}H_{20}O_5$
Methyl (4*R*)-5-acetoxy-4-(2'-methoxy-5'-methyl)phenyl-(2*E*)-pentenoate

E.e. = 96%

$[\alpha]_D^{26} +11.3$ ($c = 0.5$, CHCl₃)

Source of chirality: lipase-catalyzed hydrolysis

Absolute configuration: (4*R*)



$C_{15}H_{22}O$
(*R*)-Elvirol

E.e. >99%

$[\alpha]_D^{30} -37.1$ ($c = 0.23$, CHCl₃)

Source of chirality: lipase-catalyzed hydrolysis

Absolute configuration: (*R*)

A. Solladié-Cavallo,* M. Balaz, M. Salisova, C. Suteu,*
L. A. Nafie,* X. Cao and T. B. Freedman*

Tetrahedron: Asymmetry 12 (2001) 2605

E.r.=100/0

$[\alpha]_D^{20} = -58$ ($c = 2.2$, MeOH)


Absolute configuration: 1S,2S



Tetrahydro-4,4-dimethyl-8-hydroxy-2H-1,3-naphthoxathiane

H. J. Zhu,* B. T. Zhao, G. Y. Zuo, C. U. Pittman, Jr., W. M. Dai*
and X. J. Hao*

Tetrahedron: Asymmetry 12 (2001) 2613



(1S,3S)-1-(2-Furyl)-2-methyl-1,2,3,4-tetrahydro-β-caroline methyl ester


$[\alpha]_D = -45.0$ (c 0.506, CHCl₃)

Source of chirality: L-N-methyltryptophan

Absolute configuration: (1S,3S)

H. J. Zhu,* B. T. Zhao, G. Y. Zuo, C. U. Pittman, Jr., W. M. Dai*
and X. J. Hao*

Tetrahedron: Asymmetry 12 (2001) 2613



(1S,3S)-1-(2-Thiophenyl)-2-methyl-1,2,3,4-tetrahydro-β-caroline methyl ester



$[\alpha]_D = -54.2$ (c 0.618, CHCl₃)

Source of chirality: L-N-methyltryptophan

Absolute configuration: (1S,3S)

H. J. Zhu,* B. T. Zhao, G. Y. Zuo, C. U. Pittman, Jr., W. M. Dai*
and X. J. Hao*

Tetrahedron: Asymmetry 12 (2001) 2613




(1S,3S)-1-(2-Pyridyl)-2-methyl-1,2,3,4-tetrahydro-β-caroline methyl ester

$[\alpha]_D = -200.5$ (c 0.52, CHCl₃)

Source of chirality: L-N-methyltryptophan

Absolute configuration: (1S,3S)




$[\alpha]_D$ -88.3 (*c* 0.932, CHCl₃)

Source of chirality: L-N-methyltryptophan

Absolute configuration: (1*S*,3*S*)




(1*S*,3*S*)-1-(3-Pyridyl)-2-methyl-1,2,3,4-tetrahydro-β-caroline methyl ester




$[\alpha]_D$ +8.58 (*c* 1.37, CHCl₃)

Source of chirality: L-N-methyltryptophan

Absolute configuration: (1*S*,3*S*)




(1*S*,3*S*)-1-(2-Furyl)-3-(1-ethyl-1-hydroxypropyl)-2-methyl-1,2,3,4-tetrahydro-β-caroline




$[\alpha]_D$ +87.7 (*c* 1.55, CHCl₃)

Source of chirality: L-N-methyltryptophan

Absolute configuration: (1*S*,3*S*)




(1*S*,3*S*)-1-(2-Thiophenyl)-3-(1-ethyl-1-hydroxypropyl)-2-methyl-1,2,3,4-tetrahydro-β-caroline



$[\alpha]_D$ -189.8 (*c* 1.03, CHCl₃)

Source of chirality: L-N-methyltryptophan


Absolute configuration: (1*S*,3*S*)



(1*S*,3*S*)-1-(2-Pyridyl)-3-(1-ethyl-1-hydroxypropyl)-2-methyl-1,2,3,4-tetrahydro-β-caroline

H. J. Zhu,* B. T. Zhao, G. Y. Zuo, C. U. Pittman, Jr., W. M. Dai*
and X. J. Hao*

Tetrahedron: Asymmetry 12 (2001) 2613



C₂₂H₂₇N₃O
(1S,3S)-1-(3-Pyridyl)-3-(1-ethyl-1-hydroxypropyl)-2-methyl-1,2,3,4-tetrahydro-β-caroline


[α]_D +26.5 (*c* 0.72, CHCl₃)

Source of chirality: L-N-methyltryptophan

Absolute configuration: (1S,3S)

So Hyun Park, Hyun Jung Kang, Sangwon Ko, Soyoung Park
and Sukbok Chang*

Tetrahedron: Asymmetry 12 (2001) 2621



C₉H₁₅NO₂
(2S)-Methyl N-(2-propenyl)pyrrolidine carboxylate

E.e. >95%


[α]_D²⁵ = -11.4 (*c* 1.60, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: (2S)

So Hyun Park, Hyun Jung Kang, Sangwon Ko, Soyoung Park
and Sukbok Chang*

Tetrahedron: Asymmetry 12 (2001) 2621



C₈H₁₅NO
(2S)-N-(2-Propenyl)prolinol

E.e. >95%


[α]_D²⁵ = -33.6 (*c* 1.60, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: (2S)

So Hyun Park, Hyun Jung Kang, Sangwon Ko, Soyoung Park
and Sukbok Chang*

Tetrahedron: Asymmetry 12 (2001) 2621




C₁₀H₁₉NO₃
(2S)-N-(tert-Butyloxycarbonyl)prolinol

E.e. >95%

[α]_D²⁵ = -48.5 (*c* 1.68, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: (2S)




C₁₀H₁₈INO₂
(2S)-2-Iodomethyl-*N*-(*tert*-butyloxycarbonyl)pyrrolidine

E.e. >95%

[α]_D²⁵ = -32.8 (*c* 1.46, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (2S)




C₁₂H₂₁NO₂
(2S)-*N*-(*tert*-Butyloxycarbonyl)-2-(2-propenyl)pyrrolidine

E.e. >95%

[α]_D²⁵ = -32.4 (*c* 1.56, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (2S)




C₁₀H₁₅NO
(2S)-1-Acryloyl-2-(2-propenyl)pyrrolidine

E.e. >95%

[α]_D²⁵ = -42.4 (*c* 1.54, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: (2S)




C₈H₁₁NO
(9S)-Δ^{6,7}-Indolizidin-5-one

E.e. >95%

[α]_D²⁵ = +129.2 (*c* 0.97, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: (9S)




C₈H₁₃NO
(9*R*)-Indolizidin-5-one

E.e. >99%

[α]_D²⁵ = -6.6 (*c* 0.40, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: (9*R*)




C₁₈H₁₈O
(*S*_p)-4-Acetyl[2.2]paracyclophane

E.e. >99%

[α]_D = +65 (*c* = 0.8, CHCl₃)

Source of chirality: kinetic resolution

Absolute configuration: *S*_p




C₁₈H₂₀O
(*R*,*S*_p)-4-Acetyl[2.2]paracyclophane

E.e. >99%

[α]_D = +40 (*c* = 1.35, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: (*R*,*S*_p)




C₁₈H₂₀O
(*R*,*R*_p)-4-Acetyl[2.2]paracyclophane

E.e. = 75.8%

[α]_D = -110.4 (*c* = 1.35, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: (*R*,*R*_p)




$C_{12}H_{10}ClNO$
6-Chloro-2-pyridyl-phenylmethanol

E.e. 58%

 $[\alpha]_D^{20} = +91.6$ (*c* 1.98, CHCl₃)

Source of chirality: enantioselective functionalisation




$C_{10}H_{14}ClNO$
1-(6-Chloro-2-pyridyl)-2,2-dimethyl-1-propanol

E.e. 35%

 $[\alpha]_D^{20} = +7.1$ (*c* 1.11, CHCl₃)

Source of chirality: enantioselective functionalisation




$C_{13}H_{12}ClNO_2$
6-Chloro-2-pyridyl-4-methoxyphenylmethanol

E.e. 45%

 $[\alpha]_D^{20} = +80.2$ (*c* 1.50, CHCl₃)

Source of chirality: enantioselective functionalisation




$C_{13}H_9Cl_2NO$
4-Chlorophenyl-6-chloro-2-pyridylmethanol

E.e. 23%

 $[\alpha]_D^{20} = +37.9$ (*c* 0.98, CHCl₃)

Source of chirality: enantioselective functionalisation


 $C_{13}H_{13}NO$

5-Methyl-2-pyridyl-phenylmethanol

E.e. 39%

 $[\alpha]_D^{20} = +56.4$ (*c* 1.41, CHCl₃)

Source of chirality: enantioselective functionalisation

 $C_{12}H_{10}FNO$

6-Fluoro-2-pyridyl-phenylmethanol

E.e. 30%

 $[\alpha]_D^{20} = +37.1$ (*c* 1.01, CHCl₃)

Source of chirality: enantioselective functionalisation